Day: August 13, 2020

Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle DisordersNEWTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2020, and provided an update on the Company’s recent corporate developments.“The second quarter of 2020 was marked by significant progress in two of our lead programs – emetine and ACER-001,” said Chris Schelling, CEO and Founder of Acer. “The need for a therapeutic to treat confirmed COVID-19 patients before they progress and become hospitalized remains a global...

DALLAS, Aug. 13, 2020 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, announced today that it supported Align Capital Partners’ (“ACP”) recent acquisition of Electronic Transaction Consultants Corporation (“ETC” or the “Company”) from Italian parent company Atlantia SpA with a revolver, first lien term loan and equity co-investment. Capital Southwest led the financing transaction and will act as the sole administrative agent on the credit facility. Main Street Capital Corporation (NYSE: MAIN) and Principal Global Investors, LLC (an affiliate of Principal Financial Group, Nasdaq: PFG) were co-lenders on the term loan and the revolving...

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings call on August 13, 2020 at 4:30 p.m.Recent Corporate Highlights:Completed a $22 million public offering, led by healthcare-focused investors, to allow completion of the Company’s Phase 3 registration trial of Melphalan/HDS in liver-dominant metastatic ocular melanoma (mOM) and refiling of a New Drug Application (NDA) with FDA. Uplisted to the NASDAQ Capital Market. Announced management and board transitions. Initiated pre-commercialization work for Melphalan/HDS in mOM. Initial physician and payer surveys have highlighted the high-unmet medical need in...

Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic MedicinesCompany Continues to Progress Candidates in Huntington’s Disease (HD) and Myotonic Dystrophy (DM1)PITTSBURGH, Aug. 13, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, today reported its financial results for the three and nine month periods ended June 30, 2020.“We are pleased with the continued execution of our development programs during 2020. This includes the announcement in late-March of compelling data that firmly validate our platform as a viable fully synthetic...

WEST FARGO, N.D., Aug. 13, 2020 (GLOBE NEWSWIRE) — Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, announced today it will release financial results for the second quarter ended July 31, 2020, on Thursday, August 27, 2020, followed by an investor conference call at 7:30 a.m. Central time (8:30 a.m. Eastern time).Investors interested in participating in the live call can dial (877) 705-6003 from the U.S. International callers can dial (201) 493-6725. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, September 10, 2020, by dialing (844) 512-2921 from the U.S., or (412) 317-6671 from international locations, and entering confirmation code 13705793.There also will be a simultaneous, live webcast...

SANTA PAULA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of value-added fresh food, today announced that it will release financial results for the third quarter ended July 31, 2020, after the market closes on Tuesday, September 8, 2020.A conference call and audio webcast with analysts and investors will be held at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, to discuss the results and answer questions.Live conference call: 877-407-3982 (domestic) or 201-493-6780 (international) with conference ID: 13708329.Live and archived webcast will be available on the Events and Presentations page of Calavo’s investor relations website at http://ir.calavo.com.             About Calavo Growers, Inc.Calavo Growers, Inc. is a global avocado-industry leader and...

Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million – Lumos Pharma to receive $60 million for its 60% interest in PRVLumos Pharma reaffirms its expectation of the initiation of its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020AUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical activities.“The second quarter continued to be a busy and productive one for Lumos Pharma,” commented Rick Hawkins, Chairman, CEO and President. “Most notably, the efforts of our team during this period culminated in the sale of our Priority Review Voucher in line...

Quarterly revenue of $4.40 billion, up 23 percent year over yearGAAP EPS of $0.91 and non-GAAP EPS of $1.06, up 49 percent and 43 percent year over year, respectivelyReturned $402 million to shareholdersSANTA CLARA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. (NASDAQ: AMAT) today reported results for its third quarter ended July 26, 2020.Third Quarter ResultsApplied generated revenue of $4.40 billion. On a GAAP basis, the company recorded gross margin of 44.5 percent, operating income of $1.11 billion or 25.2 percent of net sales, and earnings per share (EPS) of $0.91.On a non-GAAP adjusted basis, the company reported gross margin of 45.0 percent, operating income of $1.16 billion or 26.4 percent of net sales, and EPS of $1.06.The company returned $402 million to shareholders including $200 million in share...

COPENHAGEN, Denmark, Aug. 13, 2020 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Thursday, August 27, 2020 at 4:30 p.m. Eastern Time (ET) to review its second quarter 2020 financial results and provide a business update.Conference Call DetailsA live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion of the event for 30 days.About Ascendis Pharma A/SAscendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.VANCOUVER, British Columbia, Aug. 13, 2020 (GLOBE NEWSWIRE) — Sigma Lithium Resources Corporation (“Sigma” or the “Company”) (TSXV: SGMA) (OTC- QB: SGMLF) is pleased to announce that it has closed its previously announced upsized non-brokered private placement and has issued 8,285,700 common shares (the “Common Shares”) at a price of C$2.15 per Common Share for gross proceeds of approximately US$13.3 million (equivalent to approximately C$17.8 million) (the “Offering”). No warrants were issued in connection with this Offering.The Offering book was oversubscribed and it was comprised, in its majority by leading global institutional investors. Other participants included mainly large global family offices. The investors in the Offering...